Clinical Trials Browser

NIH × Melanoma × tetracycline CMT-3 × Clear all

NCT00001683 2008-03-04

A Phase I Study of Oral COL-3 (NSC-683551), a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer

Phase 1 Completed

DermatologicGenitourinaryLymphoid

Carcinoma, Renal Cell, Lymphoma, Melanoma, Neoplasm Metastasis